Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Aripiprazole and impulse control disorders

higher risk with the intramuscular depot formulation?

Lertxundi, Unaxa; Hernandez, Rafaelb; Medrano, Juanc; Domingo-Echaburu, Saioad; Garcia, Montserrate; Aguirre, Carmeloe,f

International Clinical Psychopharmacology: January 2018 - Volume 33 - Issue 1 - p 56–58
doi: 10.1097/YIC.0000000000000194
SHORT COMMUNICATION
Buy

Dopamine agonists have been associated with an increased risk of developing impulse control disorders (ICDs). The US Food and Drug Administration (FDA) issued a safety warning in 2016 of a possible association between ICDs and aripiprazole. Recently, one large epidemiological study has confirmed this risk. In the present study, we aim to determine whether the safety signal of ICDs associated with aripiprazole detected by the FDA is replicated in the European pharmacovigilance database (EudraVigilance). We searched for all suspected spontaneous cases of ICDs associated with aripiprazole in EudraVigilance up to 23 February 2017. To assess the association between ICD cases and each dopamine agonist drug, we calculated the proportional reporting ratios (PRRs). Among 4 905 110 events of all types recorded in EudraVigilance, we found 160 cases of ICDs associated with aripiprazole. Aripiprazole fulfilled the criteria to generate a safety signal; PRR (95% confidence interval): 16.39 (13.97–19.24). Notably, the association seemed the strongest for the depot formulation of aripiprazole; PRR (95% confidence interval): 27.13 (17.22–42.75). Our analysis of the data contained in EudraVigilance confirms the safety signal detected last year by the FDA. Interestingly, for the first time, we show that the association seems the strongest for the intramuscular depot formulation of aripiprazole.

aPharmacy Service, Araba Mental Health Network

bInternal Medicine Service, Araba Mental Health Network, Vitoria-Gasteiz, Alava Province

cPsychiatry Service, Bizkaia Mental Health Network, Portugalete

dPharmacy Service, Alto Deba Integrated Health Care, Arrasate, Gipuzkoa Province

eBasque Pharmacovigilance Unit, Galdakao-Usánsolo Hospital, Galdakao, Bizkaia Province

fDepartment of Pharmacology, School of Medicine and Nursing, University of the Basque Country, Leioa, Spain

Correspondence to Unax Lertxundi, PhD, Pharmacy Service, Araba Mental Health Network, C/alava 43, 01006 Vitoria-Gasteiz, Alava Province, Spain Tel: +34 945 00 65 33; fax: +34 945 00 65 87; e-mail: unax.lertxundietxebarria@osakidetza.net

Received May 22, 2017

Accepted July 6, 2017

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.